Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ronald M. Goldenberg & Lori Berard. (2018) Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. Current Medical Research and Opinion 34:1, pages 1-10.
Read now
Read now
Stuart A. Ross. (2015) A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Current Medical Research and Opinion 31:1, pages 125-135.
Read now
Read now
Articles from other publishers (13)
Magdalena Kotańska, Monika Marcinkowska, Kamil J. Kuder, Maria Walczak, Marek Bednarski, Agata Siwek & Marcin Kołaczkowski. (2023) Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α2-adrenoceptor and trace amine-associated receptor 1 ligand. Pharmacological Reports.
Crossref
Crossref
Andrew P. Demidowich, Kristine Batty & Mihail Zilbermint. (2022) Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions. Diabetes Spectrum 35:4, pages 440-451.
Crossref
Crossref
Iakovos Avramidis, Athanasia Apsemidou, Antigoni Z. Lalia, Nikolaos Petridis, Euangelos Tourtouras, Georgios Kalopitas & Georgios Pilianidis. (2020) Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes. Clinical Diabetes 38:3, pages 248-255.
Crossref
Crossref
Diego Bellido, Pablo Abellán, José Manuel Ruiz Palomar, Rogelio Álvarez Sintes, Andreu Nubiolae, Virginia Bellido & Gracia Romero. (2018) Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study. Current Therapeutic Research 89, pages 37-42.
Crossref
Crossref
Stefano Genovese, Edoardo Mannucci & Antonio Ceriello. (2017) A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Advances in Therapy 34:8, pages 1791-1814.
Crossref
Crossref
Ying Cao, Fang Gao, Qian Zhang, Lingling Xu, Qian Wan, Wenqi Li, Jimin Li, Ling Wang & Yaoming Xue. (2016) Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes. Journal of Diabetes 9:5, pages 502-509.
Crossref
Crossref
Jens J. Holst, John B. Buse, Helena W. Rodbard, Sultan Linjawi, Vincent C. Woo, Trine Welløv Boesgaard, Kajsa Kvist & Stephen C. Gough. (2015) IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. Journal of Diabetes Science and Technology 10:2, pages 389-397.
Crossref
Crossref
Stefanie Amarens de Boer, Joop Daniel Lefrandt, Japke Frida Petersen, Hendrikus Hessel Boersma, Douwe Johannes Mulder & Klaas Hoogenberg. (2015) The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour. International Journal of Clinical Pharmacy 38:1, pages 144-151.
Crossref
Crossref
S. C. L. Gough, B. W. Bode, V. C. Woo, H. W. Rodbard, S. Linjawi, M. Zacho, P. D. Reiter & J. B. Buse. (2015) One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial. Diabetes, Obesity and Metabolism 17:10, pages 965-973.
Crossref
Crossref
Sarah L. Greig & Lesley J. Scott. (2015) Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes. Drugs 75:13, pages 1523-1534.
Crossref
Crossref
J. B. Buse, A. Peters, D. Russell‐Jones, S. Furber, M. Donsmark, J. Han, L. MacConell, D. Maggs & M. Diamant. (2014) Is insulin the most effective injectable antihyperglycaemic therapy?. Diabetes, Obesity and Metabolism 17:2, pages 145-151.
Crossref
Crossref
Ai Q. Li, Liang Zhao, Teng F. Zhou, Meng Q. Zhang & Xiao M. Qin. (2015) Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation. American Journal of Physiology-Cell Physiology 308:2, pages C164-C175.
Crossref
Crossref
Roberto Ravasio. (2014) Economic Impact of Therapeutic Choices: The Case of Incretins. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 1:2, pages GRHTA.5000181.
Crossref
Crossref